Cytotoxic effect after 2 h treatment at 37°C and selectivity of hybrid peptides
Code | Hemolysis (%)* | RBCs HC50 (μM) | Selectivity index (SI) | |||
---|---|---|---|---|---|---|
L929/HeLa | L929/Ca Ski | RBCs/HeLa | RBCs/Ca Ski | |||
1 | 6.3% | > 77.9 | 1.9 | 1.4 | > 3.6 | > 2.7 |
2 | 9.5% | > 77.9 | 2.1 | 1.1 | > 2.9 | > 1.6 |
3 | 25.1% | 59.2 | 2.3 | 1.8 | 4.4 | 3.5 |
4 | 16.8% | > 74.7 | 2.6 | 1.9 | > 4.7 | > 3.3 |
9 | 3.5% | > 64.9 | 1.2 | 0.7 | > 3.3 | > 1.9 |
10 | 4.2% | > 70.2 | 1.7 | 0.4 | > 5.5 | > 1.3 |
11 | 4.0% | > 68.5 | 1.5 | 0.4 | > 4.0 | > 1.0 |
12 | 4.4% | > 68.5 | 1.2 | 1.2 | > 4.0 | > 4.2 |
13 | 33.1% | 60.4 | > 6.4 | > 1.1 | 5.0 | 0.8 |
14 | 30.6% | 41.8 | 2.0 | 0.9 | 2.8 | 1.2 |
15 | 1.3% | > 80.5 | 0.5 | 0.3 | > 5.5 | > 4.1 |
16 | 1.2% | > 80.5 | > 5.1 | > 1.1 | > 5.1 | > 1.1 |
17 | 1.8% | > 83.3 | 0.7 | 0.5 | > 3.5 | > 2.4 |
18 | 35.2% | > 48.0 | 3.7 | 1.0 | > 5.0 | > 1.3 |
* Percentage of hemolysis at the IC50 determined in MTT assays in HeLa cells. RBCs: red blood cells
The supplementary materials for this article are available at: https://www.explorationpub.com/uploads/Article/file/100864_sup_1.pdf.
NAC: Conceptualization, Methodology, Investigation, Formal analysis, Writing—original draft, Visualization, Writing—review & editing. JEGC: Conceptualization, Methodology, Formal analysis, Resources, Writing—original draft, Visualization. CMPG: Formal analysis, Resources, Writing—original draft. YVC: Formal analysis, Resources, Writing—original draft. ACBC: Formal analysis, Resources, Writing—original draft. RFM: Conceptualization, Supervision. ZJRM: Conceptualization, Methodology, Resources, Writing—review & editing. JERM: Conceptualization, Methodology, Writing—review & editing. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.
This research was conducted with the financial support of MinCiencias with the project: “Obtención de un prototipo peptídico promisorio para el desarrollo de un medicamento de amplio espectro para el tratamiento del cáncer de colon, cuello uterino y próstata”. Contract RC No. 845-2019. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2024.